Skip to content

Misopristol Versus Pitocin for Second Trimester Abortion

Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00784797
Enrollment
145
Registered
2008-11-04
Start date
2009-01-31
Completion date
2012-06-30
Last updated
2013-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion, Missed

Brief summary

Second trimester abortion can be done surgically or medically. Medical abortion with mifepristone and misopristol is one of the common protocol, but misopristol have high rate side effect. The investigators recent study proved the efficacy of pitocin after mifepristone in second trimester abortion with minimal side effects. Working hypothesis and aims: To compare misopristol and pitocin after mifepristone preparation in second trimester in seccess rate, interval to abortion, side effects and patient satisfaction.

Interventions

DRUGmifepristone and misopristol

200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses

DRUGmifepristone and oxytocin

200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* midtrimester late abortion * midtrimester induced abortion

Exclusion criteria

* placenta previa * infected abortion * rupture of membranes * s/p cesarean section \*2 or more

Design outcomes

Primary

MeasureTime frame
Success rate of abortion24 hours
Interval to abortion24 hours

Secondary

MeasureTime frame
Side effects24 hours

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026